{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"12","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"A response was defined as either a confirmed or unconfirmed complete or partial responses as defined by RECIST. A complete response (CR) was defined as the disappearance of all disease. A partial response (PR) was defined as a \\>= 30% decrease in the sum of longest diameters of target lesions. A CR or PR was considered confirmed if two consecutive determinations were made at least 4 weeks apart.","dispersionType":"95% Confidence Interval","groups":[{"description":"Daily oral Everolimus 10 mg/day\n\neverolimus","id":"OG000","title":"Everolimus"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Every 8 weeks until disease progression, up to 3 years.","title":"Response","type":"SECONDARY","unitOfMeasure":"percentage of overall response rate"}